Insider selling volume is sub-material (0.016% of cap) and entirely compensation-driven. This cluster does not signal operational concern. Monitor next quarterly earnings for any guidance change or pipeline update that could drive the stock, the 30d prior insider flow was 2 sales at $2.1M, consistent with routine diversification. No trade-level action warranted.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 3 $164.23entry
- T+1 · 6mo ago +1.58%α +1.18% · $166.83
- T+5 · 5mo ago −2.05%α +1.77% · $160.86
- T+20 · 5mo ago +2.16%α +3.28% · $167.77
- T+60 · 3mo ago −5.36%α −7.59% · $155.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three C-suite officers at Neurocrine Biosciences sold a total of ~$2.73M in open-market shares within a 7-day window. All sales followed derivative exercises (non-cash M and A), and one officer (Boyer D.) sold without a prior M, which is routine compensation-driven selling. At $16.6B market cap, the cluster is ~0.016% of cap, below the 0.1% materiality floor for insider sales, rendering the cluster classificationally trivial. Per the asymmetry rule for sales (Alldredge 2019), no amplification is applied.
Key Financial Metrics
Key Facts
- Cluster: 3 C-suite officers sold ~2.73M in open-market shares over 7 days (May 26, June 2, 2026)
- Largest sale: CSO Onyia Jude sold $1.76M (11K shares at ~$160.25) after exercising options
- CRO Delaet Ingrid sold $354K; Chief Corp. Affairs Boyer D.W. sold $609K; CMO Keswani had only non-cash derivative activity
- Total open-market sales: ~$2.73M, or ~0.016% of $16.6B market cap, below the 0.1% materiality floor
- All sales were preceded by derivative exercises (M) or grants (A), consistent with compensation liquidity, not information-motivated selling
- No 10b5-1 plan designation was filed for any of these trades; non-10b5-1 sales carry slightly more signal than plan sales, but at 0.016% of cap the absolute magnitude is noise
Financial Impact
~$2.73M in insider open-market sales; immaterial relative to $16.6B market cap
Risk Factors
- Insider selling at low volume but by multiple C-suite members could indicate private caution even if below materiality floor
- Stock has significant pipeline concentration risk (Ingrezza, crinecerfont); any Phase 3/regulatory setback would hit all holders regardless of insider activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1780610096737 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers